Sisram Medical Launches Local Manufacturing in China with Alma Rejuve Production

Sisram Medical Ltd, a notable player in the wellness industry, recently marked a significant milestone with the opening of its manufacturing facility in Miyun, Beijing. This state-of-the-art facility is the company's first manufacturing site in China and has commenced operations with its first locally produced device, the Alma Rejuve. This development aligns with Sisram's localization strategy aimed at increasing the efficiency and responsiveness of its operations globally.

The factory was established through a partnership between Sisram Medical (Tianjin) Ltd, a wholly-owned subsidiary of Sisram, and Sinmait Medical Technology (Beijing) Co., Ltd. By utilizing the proven production standards and quality control measures from their Israeli operations, Sisram aims to implement local production upgrades which are essential for meeting the growing demand for aesthetic solutions in China. These enhancements will not only help maintain high-quality standards but also streamline production processes.

Alma Rejuve is recognized in the Chinese market for its effectiveness in anti-aging treatments and skin rejuvenation. With local production becoming a reality, this product's availability is expected to skyrocket, making it more accessible to clinics and consumers alike. The facility is strategically positioned to enhance supply chain operations, improve delivery times, and maintain consistent product quality across the board.

Furthermore, this new site will not only serve the expansive domestic market but is also poised to support Sisram's broader goals in the Asia-Pacific (APAC) region. With the adaptation of automated and intelligent manufacturing processes, Sisram seeks to address regional demands effectively while setting a solid foundation for future growth in APAC. The ability to respond rapidly to market needs—as well as the integration of R&D, production, sales, and after-sales support under one roof—demonstrates the company’s commitment to a customer-centric approach.

Mr. Jiahong Li, Co-CEO and CFO of Sisram, emphasized the importance of this facility, stating, "This marks a new chapter in Sisram’s localization strategy. By strengthening our local operations, we aim to build a more resilient and competitive ecosystem in China." This approach not only enhances product availability but also propels Sisram closer to its goal of being a leader in providing integrated aesthetic solutions.

As more consumers gravitate towards comprehensive wellness experiences, Sisram is dedicated to leading the charge in fulfilling these needs. The synergy between Energy-Based Devices (EBD) and injectables is set to redefine how aesthetic care is delivered, ensuring that customers receive a holistic treatment experience.

In conclusion, the opening of Sisram’s Beijing facility and the production of the Alma Rejuve device represent a pivotal step towards achieving extensive operational efficiency and market adaptability. The strategic vision laid out by the company is expected to enhance its competitive edge and ultimately serve as a significant growth engine for Sisram Medical across APAC and beyond. As the wellness industry continues to evolve, Sisram’s investment in localized manufacturing underscores both its commitment to innovation and its dedication to providing superior aesthetic solutions to consumers worldwide.

For further information about Sisram Medical and its offerings, visit www.sisram-medical.com.